Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 3;32(4):227–239. [Article in Spanish] doi: 10.1016/S0212-6567(03)79257-9

Utilidad clínica de los marcadores tumorales séricos

A Martín Suárez a, L Alonso Díaz a, I Ordiz Álvarez a, J Vázquez b, F Vizoso Piñeiro c,*
PMCID: PMC7668714  PMID: 12975087

The content is available as a PDF (349.4 KB).

Bibliografía

  • 1.Magdelénat H. Tumor markers in oncology:past, present an future. J Immunol Methods. 1992;150:133–143. doi: 10.1016/0022-1759(92)90072-2. [DOI] [PubMed] [Google Scholar]
  • 2.Ascheim S., Zondek B. Das Hormon des Hypophysen vorderlappens: testobjekt zum Nachweis des. Klin Wochenschr. 1927;6:248–252. [Google Scholar]
  • 3.Brown W.H. A case of pluriglandular syndrome: «diabetes of bearded women». Lancet. 1928;215:1022–1023. [Google Scholar]
  • 4.Gutman A.B., Gutman E.B. An «acid» phosphatasen occurring in the serum of patients. J Clin Invest. 1938;17:473–478. doi: 10.1172/JCI100974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Abelev G.I. Production of embryonal serum alpha globulin by hepatomas. Review of experimental. Cancer Res. 1963;28:1344–1350. [PubMed] [Google Scholar]
  • 6.Gold P., Freeman S.O. Demostration of tumour- specific antigens in human colonic carcinomata by inmunological intolerance and absorption techniques. J Exp Med. 1965;121:439–445. doi: 10.1084/jem.121.3.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Köhler H., Millstein C. Continuous cultures of fused cellssecreting antibody of pre-defined specificity. Nature. 1975;256:495. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  • 8.Bast R., Ravdin P., Hayes D., Fritsche H., Jessup J.M. 2000 updates of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of ClinicalOncology. J Clin Oncol. 2001;19:1865–1878. doi: 10.1200/JCO.2001.19.6.1865. [DOI] [PubMed] [Google Scholar]
  • 9.Ruibal A. Grafur; Madrid: 1990. (Consideraciones acerca de los marcadores tumorales en el cáncer de mama). [Google Scholar]
  • 10.Vizoso F., Allende M.T., Díez M.C., Ruibal A. Evidence of a correlation between CA 15.3 and estradiol serum levels in women with fibrocystic. Int JBiol Markers. 1991;6:33–34. doi: 10.1177/172460089100600107. [DOI] [PubMed] [Google Scholar]
  • 11.Vizoso F., Allende M.T., Fueyo A., Riera L., López- Otín C., Ruibal A. Evidence of a correlation between CA 15.3 and prolactin serum levels after TRH administration in women with gross cystic breast disease. Int J Biol Markers. 1991;6:31–32. doi: 10.1177/172460089100600106. [DOI] [PubMed] [Google Scholar]
  • 12.Buffaz P., Gauchez A., Caravel J., Vuillez J.P., Cura C., Agrius-Delord C. Can tumor marker assays be a guide in the prescription of bone scan for breast and lung cancersα. Eur J Nucl Med. 1999;26:8–11. doi: 10.1007/s002590050352. [DOI] [PubMed] [Google Scholar]
  • 13.Nicolini A., Carpi A., Ferrari P., Sagripanti A., Anselmi L. A multistep therapy with subcutaneous low dose recombinat interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. Biomed Pharmacother. 1998;52:311–316. doi: 10.1016/s0753-3322(98)80027-9. [DOI] [PubMed] [Google Scholar]
  • 14.Molina R., Farrus B., Filella J., Zanon G., Pahaisa J., Latre M. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse. Anticancer Research. 1999;19:2557–2562. [PubMed] [Google Scholar]
  • 15.`Cheung K.L., Graves C.R., Robertson J.F. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev. 2000;26:91–102. doi: 10.1053/ctrv.1999.0151. [DOI] [PubMed] [Google Scholar]
  • 16.Sütterlin M., Bussen S., Trott S., Caffier H. Predictive value of CA 15.3 in the follow up of invasive breast cancer. Anticancer Research. 1999;19:2567–25670. [PubMed] [Google Scholar]
  • 17.Bast R., Ravdin P., Hayes D., Battes S., Fritsche H., Jessup J.M. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer. clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865–1878. doi: 10.1200/JCO.2001.19.6.1865. [DOI] [PubMed] [Google Scholar]
  • 18.Stearns V., Yamauchi H., Hayes D. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat. 1998;52:239–259. doi: 10.1023/a:1006137619153. [DOI] [PubMed] [Google Scholar]
  • 19.Robertson J.F., Jaeger W., Syzmendera J.J., Selby C., Loleman R., Howell A. The objective measurement of remission and progression in metastatic. Eur J Cancer. 1999;35:47–53. doi: 10.1016/s0959-8049(98)00297-4. [DOI] [PubMed] [Google Scholar]
  • 20.Lauro S., Trasatti L., Bordin F., Lanzetta G., Bria E., Gelibter A. Comparison of CEA, MCA, CA15-3 and CA 27-29 in follow- up and monitoring therapeutic response in breast cancer patients. Anticancer Res. 1999;19:3511–3516. [PubMed] [Google Scholar]
  • 21.Ebeling F., Schmitt U.M., Untch M., Nagel D., Fateh-Moghadam A., Stieber P. Tumour markers CEA and CA15-3 as prognostic factors in breast cancer-univariate and multivariatein breast cancer-univariate and multivariate analysis. Anticancer Res. 1999;19:2545–2550. [PubMed] [Google Scholar]
  • 22.Horobin J.M., Browning M.L., McFarlane N.P., Smith G., Preece P.E., Wood R.A. Potential use of tumor marker CA 15.3 in the staging and prognosis of patients with breast cancer. JR Coll Surg Edinb. 1991;36:219–221. [PubMed] [Google Scholar]
  • 23.Duffy M.J., Maguire T.M., Hill A., Mc Dermott, O’Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasiS. Breast Cancer Res. 2000;2:252–257. doi: 10.1186/bcr65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Mc Laughlin R., Mc Grath J., Grimes H., Given H.F. The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patient with breast cancer. Int J Biol Markers. 2000;15:340. doi: 10.1177/172460080001500412. [DOI] [PubMed] [Google Scholar]
  • 25.Shering SG., Sherry F., McDermott E.W., O’Higgins N.J., Duffy M.J. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Cancer. 1998;83:2521–2527. [PubMed] [Google Scholar]
  • 24.Hilkens J., Ligtenberg M.J., Vos H.L., Lituinov S.V. Cell membrane-associated mucins andtheir adhesion-modulating property. Trends Biochem Sci 1992;17:359-63. 1992;17:359–363. doi: 10.1016/0968-0004(92)90315-z. [DOI] [PubMed] [Google Scholar]
  • 27.Taylor-Papadimitriou J., Burchell J., Miles D.W., Dalziel M. MUC1 and cancer. Biochim Biophys Acta. 1999;1455:301–313. doi: 10.1016/s0925-4439(99)00055-1. [DOI] [PubMed] [Google Scholar]
  • 28.Spicer A.P., Rowse G.J., Lidner T.K., Gendler S.J. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem. 1995;270:3093–3101. doi: 10.1074/jbc.270.50.30093. [DOI] [PubMed] [Google Scholar]
  • 29.Schwartz M.K. Circulating and tissue markers in the longitudinal management of breastcancer patients. Adv Exp Med Biol. 1994;353:47–53. doi: 10.1007/978-1-4615-2443-4_6. [DOI] [PubMed] [Google Scholar]
  • 30.Allende M.T., Fernández Llana, Rodríguez Álvarez J.M., Ruiz M.C., Vizoso F., Ruibal A. BCM-Imx and CA 15.3 serum levels in patients with breast cancer: a comparative study. Bull Cancer. 1991;78:743–745. [PubMed] [Google Scholar]
  • 31.`Vizoso F., Ildefonso C., Martínez A. Proteínas inducibles por andrógenos y cáncer de mama. Rev Senología y Patol Mam. 1998;11:20–26. [Google Scholar]
  • 32.Catalona W.J., Partin A.W., Slawin K.M., Brawer M.C., Flanigan R.C., Patel A. Use of thepercentage of free prostate-specific antigen to enhace. Jama. 1998;279:1542–1547. doi: 10.1001/jama.279.19.1542. [DOI] [PubMed] [Google Scholar]
  • 33.Vashi A.R., Wonjno K.L., Henricks W., England B.A., Vessella R.L., Lange P.H. Determination of the «reflex range» and appropiate cutpoints for percent free prostete-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology. 1997;49:19–27. doi: 10.1016/S0090-4295(96)00511-0. [DOI] [PubMed] [Google Scholar]
  • 34.Carter H.B., Pearson J.D., Metter E.J., Brant L.J., Chan D.W., Andres R. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. Jama. 1992;267:2215–2220. [PMC free article] [PubMed] [Google Scholar]
  • 35.Thomas C.M.G., Sweep C.G.J. Serum tumor markers: past, state of the and future. Int J Biol Markers. 2001;16:73–86. [PubMed] [Google Scholar]
  • 36.Van Lersel M.P., Thomas C.M.G., Segers M.F.G., Witjes W.P.J., Debruyne F.M.J., Oosterhof G.O.N. The use of «ultrasensitive» prostatespecific antigen assays in the detection of biochemical recurrence after radical prostaectomy. Br J Urol. 1996;77:418–422. doi: 10.1046/j.1464-410x.1996.91017.x. [DOI] [PubMed] [Google Scholar]
  • 37.Gold P. Specific caicinoembryonic antigens of the human digestive system. J Exp Med. 1965;122:467–481. doi: 10.1084/jem.122.3.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Cutait R., Alves V.A., Lopes L.C. Restaging of colorectal cancer based on the identification of lymph node micrometastases though immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum. 1991;34:917–920. doi: 10.1007/BF02049708. [DOI] [PubMed] [Google Scholar]
  • 39.Wang J.Y., Tang R., Chiang J.M. Value of carcinoembryonicantigen in the management of colorectal cancer. Dis Colon Rectum. 1994;37:272–277. doi: 10.1007/BF02048166. [DOI] [PubMed] [Google Scholar]
  • 40.American Society of Clinical Oncology(ASCO). 1997 update and recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol. 1998;16:793–795. doi: 10.1200/JCO.1998.16.2.793. [DOI] [PubMed] [Google Scholar]
  • 41.American Society of Clinical Oncology (ASCO). 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol. 1999;17:1080–1082. doi: 10.1200/JCO.1999.17.3.1080. [DOI] [PubMed] [Google Scholar]
  • 42.American Society of Clinical Oncology (ASCO). 2000 update of American Society of Clinical oncology colorectal cancer surveillance guidelines. J Clin Oncol. 2000;18:3586–3588. doi: 10.1200/JCO.2000.18.20.3586. [DOI] [PubMed] [Google Scholar]
  • 43.American Society of Clinical Oncology (ASCO). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol. 1996;14:2843–2877. doi: 10.1200/JCO.1996.14.10.2843. [DOI] [PubMed] [Google Scholar]
  • 44.Schwartz M.K. Current status of tumor markers. Scand J Clin Lab Invest. 1995;221:5–12. doi: 10.3109/00365519509090558. [DOI] [PubMed] [Google Scholar]
  • 45.Wanebo H.J., Rao B., Pinsky C.M., Hoffman R.G., Stearns M., Schwartz M.K. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med. 1978;299:448–451. doi: 10.1056/NEJM197808312990904. [DOI] [PubMed] [Google Scholar]
  • 46.Wolmark N., Fisher B., Wieand H.S., Henry RS., Lerner H., Gordon P.H. The prognostic significance of preoperative carcinoembryonic antigens levels in colorectal cance. Ann Surg. 1984;199:375–381. doi: 10.1097/00000658-198404000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Filella X., Fuster J., Molina R., Gram J.J., García-Valdecasas J.C., Granda L. TAG-72,CA 19.9 and CEA as tumor markers in gastric cancer. ActaOncologica. 1994;33:747–751. doi: 10.3109/02841869409083943. [DOI] [PubMed] [Google Scholar]
  • 48.Díez M., Cerdán F.J., Pollan M., Maestro M.L., Ortega M.D., Martínez S. Ostic significance of preoperative serum CA 19.9 assay in patients with colorectal carcinoma. Anticancer Res. 1994;14:2819–2825. [PubMed] [Google Scholar]
  • 49.Chapman M.A.S., Buckley D., Hensos D.B., Armitage N.C. Preoperative carcinoembryoic antigen is related to tumor stage and long-term survival in colorectal cancer. Br J Cancer. 1998;78:1346–1349. doi: 10.1038/bjc.1998.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Allende T., García Muñiz J.L., Del Casar J.M. Niveles séricos preoperatorios del CEA y pronóstico en el cáncer colorrectal. Rev Esp Med Nuclear. 2001;20:358–364. doi: 10.1016/s0212-6982(01)71974-x. [DOI] [PubMed] [Google Scholar]
  • 51.Bleiberg H. Continuing the fight against advanced colorectal cancer: new and future treatment options. Anticancer Drugs. 1997;9:18–28. doi: 10.1097/00001813-199801000-00002. [DOI] [PubMed] [Google Scholar]
  • 52.Labianca R., Pessi M.A., Zamparelli G. Treatment of colorectal cancer. Current guidelines and future prospects for drugtherapy. Drugs. 1997;53:593–607. doi: 10.2165/00003495-199753040-00005. [DOI] [PubMed] [Google Scholar]
  • 53.Ruibal Morell A. Los marcadores tumorales de secreción: algo más que indicadores clínicos. Rev Esp Med Nuclear. 2001;20:349–352. doi: 10.1016/s0212-6982(01)71972-6. [DOI] [PubMed] [Google Scholar]
  • 54.Von Kleist S., Hesse Y., Kananeeh H. Comparative evaluation of four tumor markers, CA242, CA19.9, TPA, and CEA in carcinomas of the colon. Anticancer Res. 1996;16:2325–2332. [PubMed] [Google Scholar]
  • 55.Andicoechea A., Vizoso F., Alexandre E., Cuesta E., Cruz Díez M., Riera L. Preoperative carbohydrate antigen 195 (CA195) and CEA serum levels as prognostic factors in patients with colorectal cancer. Int J Biol Markers. 1998:158–164. [PubMed] [Google Scholar]
  • 56.González A., Vizoso F., Manzanares J., Ruibal A., Balibrea J.L. TAG-72 como marcador tumoral en el cáncer colorectal. Estudio comparative con el CEA. Cir Esp. 1997;62:180–184. [Google Scholar]
  • 57.Sturgeon C., Aronson A.C., Duffy M.J. European Group on tumour markers: consensus recomendations. Anticancer Res. 1999;19:2785–2820. [Google Scholar]
  • 58.Wobbes T., Thomas C.M.G., Sefers M.F.G., Nagengast F.M. Evaluation of seven tumor markers (CA50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer. 1992;69:2036–2041. doi: 10.1002/1097-0142(19920415)69:8<2036::aid-cncr2820690805>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  • 59.González A., Vizoso F., Allende M.T., Sánchez M.T., Balibrea J.L., Ruibal A. Preoperative CEA anf TAG-72 serum levels as prognostic indicators resectable gastric carcinoma. Int J Biol Markers. 1996:165–171. doi: 10.1177/172460089601100305. [DOI] [PubMed] [Google Scholar]
  • 60.González A., Vizoso F., Ais Conde G., Allende M.T., Sánchez M.T., Balibrea Q J.L. TAG-72 y CEA como marcadores tumorales en el cáncer gástrico. Cir Esp. 1996;59:473–477. [Google Scholar]
  • 61.Kawa S., Tokoo M., Hasebe O., Hayashi K., Imai H., Oguchi H. Comparative study of CA242 and CA 19.9 for the diagnosis of pancreatic cancer. Br J Cancer. 1994;70:481. doi: 10.1038/bjc.1994.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Haglund C., Lundin J., Kuusela P., Roberts P.J. CA242, a new tumor marker for pancreatic cancer: a comparison with CA19.9, CA 50 and CEA. Br J Cancer. 1994;69:515. doi: 10.1038/bjc.1994.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Andicoechea A., Vizoso F., Alexandre E., Martínez A., Cruz Díez M., Riera L. Comparative study of carbohidrate antigen 195 and carcinoembryonic antigen for the diagnosis of pancreatic carcinoma. World J Surg. 1999;23:227–232. doi: 10.1007/pl00013182. [DOI] [PubMed] [Google Scholar]
  • 64.Di Bisceglie A.M., Rustgi V.K., Hoffnagle H.J., Dusheiko G.M., Lotze MT. Hepatocellular carcinoma. Ann Int Med. 1988;108:390–401. doi: 10.7326/0003-4819-108-3-390. [DOI] [PubMed] [Google Scholar]
  • 65.Ince N., Wands J.R. The increasing incidence of hepatocellular carcinoma. N Engl J Med. 1999;340:798–799. doi: 10.1056/NEJM199903113401009. [DOI] [PubMed] [Google Scholar]
  • 66.Lamerz R. AFP isoforms and their clinical significance (overview) Ticancer Res. 1997;17:2927–2930. [PubMed] [Google Scholar]
  • 67.Foster R.S., Nichols C.R. Testicular cancer: what’s new in staging, prognosis, and therapy. Oncology. 1999;13:1689–1694. [PubMed] [Google Scholar]
  • 68.Disaia P., Creasman W. Oncología ginecológica clínica. 4.aed. Mosby. 1994:425. [Google Scholar]
  • 69.Ole G., Kaneli H., Schenker J.G. Granulosa cell tumor in Israel: an study of 172 cases. Ginecol Oncol. 1983;15:278–286. doi: 10.1016/0090-8258(83)90083-5. [DOI] [PubMed] [Google Scholar]
  • 70.Schwartz P.E. Sex cords stromal tumors of the ovary. En: Piver MS, editor. Ovarian malignancies,diagnostic and therapeutic advances. Churchill-Livingstone. 1987:251–271. [Google Scholar]
  • 71.Lappöhn R.E., Burger H.G., Bouman J., Bangah M., Krans M., De Bruijm H.W. Inhibin as a marker for granulosa-cell tumors. N Engl J Med. 1989;321:790–793. doi: 10.1056/NEJM198909213211204. [DOI] [PubMed] [Google Scholar]
  • 72.Boffess J.E., Soules M.R., Gojj B.A., Greer B.E., Cain J.M., Tamini H.K. Serum inhibin and disease status in women with ovarian granulose cell tumors. Gynecol Oncol. 1997;64:64–69.. doi: 10.1006/gyno.1996.4520. [DOI] [PubMed] [Google Scholar]
  • 73.Phocas I., Sarandanou A., Sikiotis K., Rizos A., Kaiambokis A., Zourlas P.A.A. Comparative study of serum alphabeta inmunoreactive inhibin and tumor associated antigens CA125 and CEA in ovarian cancer. Anticancer Res. 1996;16:3827–3831. [PubMed] [Google Scholar]
  • 74.Black R.S., Bray F., Ferlay J., Parkin A.M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997;7:1075–1107. doi: 10.1016/s0959-8049(96)00492-3. [DOI] [PubMed] [Google Scholar]
  • 75.Wingo P.A., Tong T., Bolden S. Cancer statistics 1995. Cancer J Clin. 1995;45:8–30. doi: 10.3322/canjclin.45.1.8. [DOI] [PubMed] [Google Scholar]
  • 76.Jacobs I., Bast R.C. The CA125 tumor-associated antigen: a review of the literature. Hum Reprod. 1989;4:1–12. doi: 10.1093/oxfordjournals.humrep.a136832. [DOI] [PubMed] [Google Scholar]
  • 77.Bast R.C., Klug T.L., St. John E.R., Jenison E., Niloff J.M., Lazarus H. A radio immunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  • 78.Schutter E.M.J., Kenemans P., Sohn C., Kristen P., Grombach G., Mobus V. Diagnostic value of pelvic examination, ultrasound and serum CA125 in postmenopausal women with a pelvic mass. Cancer. 1994;74:1398–1406. doi: 10.1002/1097-0142(19940815)74:4<1398::aid-cncr2820740433>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  • 79.Rustin G.J., Neltrop A.E., Bentzen S.M., Piccart MJ., Bertelsen K. Use of tulor markers in monitoring the course of ovarian cancer. Nn Oncol. 1999;10:21–27. doi: 10.1023/a:1008351216605. suppl. [DOI] [PubMed] [Google Scholar]
  • 80.NIH Consensus Development Panel of Ovarian Cancer. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol. 1994;55:4–14. doi: 10.1006/gyno.1994.1332. [DOI] [PubMed] [Google Scholar]
  • 81.Sturgeon C., Aronsson A.C., Duffy M.J., Hansson L.O., Klapdor R., Van Dalen A. European Group on Tumor Markers: consensus recomendations. Anticancer Res. 1999;19:2785–2820. [Google Scholar]
  • 82.Jacobs I., Stabile I., Bridges J., Kemsley P., Reynolds C., Grudzinskas J. Multimodal approach to screening for ovarian cancer. Lancet. 1988;1:268–271. doi: 10.1016/s0140-6736(88)90351-0. [DOI] [PubMed] [Google Scholar]
  • 83.Bolli J.A., Doering A.L., Bosscher J.R., Day T.G., Rao C.V., Kelly B. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 1994;55:169–173. doi: 10.1006/gyno.1994.1272. [DOI] [PubMed] [Google Scholar]
  • 84.Duk J.M., Groenier K.H., de Bruijn H., Hollema H., ten Hoor K.A. Pre-treatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early satge cervical cancer. J Clin Oncol. 1996;14:118–119. doi: 10.1200/JCO.1996.14.1.111. [DOI] [PubMed] [Google Scholar]
  • 85.Duk J.M., De Bruijn H., Fleuren G.J., Aalders J.G. Adenocarcinoma of the uterine cervix: prognostic significance of pre-treatment serum CA125, squamous cell carcinoma antigen and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics. Cancer. 1990;65:1830–1837. doi: 10.1002/1097-0142(19900415)65:8<1830::aid-cncr2820650828>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES